sarcoma with BCOR genetic alterations

Summary

sarcoma with BCOR genetic alterations (MONDO:0958159) is a cancer and 1 clinical trial. Top therapeutic interventions include fludeoxyglucose f 18, ifosfamide, and regorafenib. A subtype of small cell sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	sarcoma with BCOR genetic alterations
Mondo ID	MONDO:0958159
DOID	DOID:0081402
NCIT	C178465
UMLS	C5555057
MedGen	1791498
Is cancer (heuristic)	yes

Disease family

This is a subtype of small cell sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › sarcoma › small cell sarcoma › sarcoma with BCOR genetic alterations

Related subtypes (5): small cell osteogenic sarcoma, mesenchymal chondrosarcoma, desmoplastic small round cell tumor, EWSR1-negative small round cell tumor, round cell sarcoma with EWSR1-non-ETS fusion

Subtypes (3): BCOR ITD sarcoma, BCOR-CCNB3 sarcoma, childhood sarcoma with BCOR genetic alterations

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06820957	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLUDEOXYGLUCOSE F 18	4	1
IFOSFAMIDE	4	1
REGORAFENIB	4	1
CHEMBL541887	0	1